Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia® (denosumab), to treat a variety of debilitating bone conditions. Teva’s proposed biosimilar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results